Monsenso’s mobile health solution will be used in H2020 Funded ECoWeB Project

Monsenso’s mobile health solution will be used in H2020 Funded ECoWeB Project

Monsenso’s mHealth solution will feature additions for the ECoWeB project, which focuses on training and enhancing emotional competency skills for youth populations    

Copenhagen, Denmark24 April 2018 Monsenso is happy to announce the involvement of our mHealth solution in the Horizon 2020 Funded ECoWeB Project.

The ECoWeB project aims to provide a comprehensive and personalized mobile app that will train young individuals in enhancing their emotional control skills and minimizing their emotional deficits. Monsenso’s mHealth solution is the foundation for the project. The app will work closely with the 3 major components of Emotional Control: Production, Regulation & Knowledge. It is hypothesized that interventions based on such comprehensive assessments will efficiently increase resilience toward adversity, promote mental wellbeing and act as a primary prevention for mental disorders.

“The Monsenso mHealth solution offers a perfect foundation for the ECoWeB project. I am confident that the routine monitoring, and high customizability of the solution can be modified to help young individuals enhance important emotional competency skills.” says Ed Watkins, Professor of Experimental and Applied Clinical Psychology at the College of Life & Environmental Sciences for Exeter University.

This project adopts a new approach to the fundamental understanding of emotion, by combining a highly personalized approach to understanding the individual and leading digital technology. This innovative approach has the potential to deliver a breakthrough in the effective prevention of mental disorders.

The ECoWeB project will integrate the following three multidisciplinary approaches:

  1. The use of the theoretical model of normal emotional functioning (The Emotional Competence Process) to guide the identification and targeting of emotional competence mechanisms implicated in both the mental wellbeing and psychopathology for young people.
  2. The systematic assessment of personal Emotional Competence profiles to select targeted interventions to promote wellbeing
  3. Mobile application delivery intended for scalability, accessibility and adaptability in younger populations.

“This project is exciting because it diversifies the usage of our solution. In addition to providing a supplement for treatment in clinical practice, our solution will now be able to also be used independently to provide personalized prevention.” says Thomas Lethenborg, CEO at Monsenso.

The project is led by The University of Exeter. The consortium consists of the following members:

The project was developed in response to the need for more robust evidence on resilience factors and effective interventions for young populations, in addition to the need for scalable approaches to mental health interventions that are accessible at a population level.

The project is presently ongoing.

Click here to read the press release in Danish. 

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No.754657. 

Monsenso provides medication adherence and behavioural monitoring components in H2020 Funded R-LiNK Study

Monsenso provides medication adherence and behavioural monitoring components in H2020 Funded R-LiNK Study

Monsenso’s mHealth solution participates in the R-LiNK Study, a major new study for optimising treatment response to lithium

Copenhagen, Denmark – 16 April 2018  Monsenso is proud to announce our participation in R-LiNK – the major new study for developing a more complete understanding of the reactions and effects of taking lithium. As a part of this study, our solution will be implemented for 300 participants across 15 centres all over Europe.

Lithium is the leading treatment for patients with bipolar disorder. There is a large variability across patient responses when taking lithium. This variability makes it difficult for clinicians to predict how patients will respond to being prescribed lithium.

“Lithium is the oldest drug treatment used regularly in psychiatry and one that has shown evidence of many benefits over the decades it has been used. However, only about one third of patients are “excellent” responders with a future two thirds showing partial or no response. This large EU funded study takes place across Europe and aims to find out which “biomarkers” can be used to predict which patients will respond and for those whom lithium will not help,” said Professor Allan Young, Director of the Centre for Affective Disorders at the Institute of Psychiatry, Psychology & Neuroscience, King’s College London.

R-Link is a multimodal approach to studying lithium initiation, and identifying important biomarkers from receiving lithium treatment. The comprehensive study aims to identify factors related to better responses, safety, and tolerability of lithium treatment. The results of the study can help provide patients and clinicians alike with more accurate information to make informed decisions regarding the prescription of lithium, therefore improving the long term management and prognosis for bipolar patients.

“Mobile health technology can provide new insight into the treatment of mental health and disorders, and mobile phone usage can also provide important new biomarkers for affective disorders.” said Professor Lars Kessing, of the Psychiatric Center Copenhagen and the University of Copenhagen, Faculty of Health Sciences.

The Monsenso mHealth solution will be involved in the phase of the study that will conduct a qualitative and quantitative study on the acceptability and efficacy of connected ecological devices to monitor mood, lithium levels, symptoms, daily behaviour, and enhance patient adherence. Therefore, the solution will include data collection of lithium adherence and outcome/behaviour reporting (via sensor data and daily self-assessment).

“Ensuring adherence to medical treatment on an individual level is key to a successful mental health treatment. Our mHealth solution will contribute to this study by promoting medical adherence, through providing easy, personalised self-monitoring and medication tracking, as well as medication reminders.” said Thomas Lethenborg, CEO of Monsenso.

This study also has the potential to enable the personalisation of lithium based treatment. Findings from this study can also contribute to the overall prevention and reduction of unnecessary side effects from lithium treatment as well as overall ineffective treatments.
Monsenso is now involved in more than ten pan European and domestic research projects in the mental health & affective disorders field.

The study is presently ongoing.

Click here to read the press release in Danish. 

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No.754907.